# A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin

> **NCT04662164** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Shanghai HEP Pharmaceutical Co., Ltd.**

## Conditions studied

- Type 2 Diabetes Patients

## Interventions

- **DRUG:** hepalatide

## Key facts

- **NCT ID:** NCT04662164
- **Lead sponsor:** Shanghai HEP Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Not approved by CFDA
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04662164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04662164, "A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04662164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*